acitretin / Generic mfg. - LARVOL DELTA

Retrospective Cohort Study on the Effects of Secukinumab versus Acitretin Capsules in Preventing the Progression of Moderate-to-Severe Plaque Psoriasis to Psoriatic Arthritis (ChiCTR) - P4 | N=3191 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Army Medical University PLA; The First Affiliated Hospital of Army Medical University PLA

New P4 trial • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Clinical evaluation of acupuncture with enhanced efficacy and reduced toxicity as an adjuvant to acitretin in the treatment of moderate to severe psoriasis vulgaris and its mechanism of action based on "treating the skin from the intestine" (ChiCTR) - P=N/A | N=120 | Not yet recruiting | Sponsor: Chengdu Pidu District Hospital of Traditional Chinese Medicine; Chengdu Pidu District Hospital of Traditional Chinese Medicine

New trial • Dermatology • Immunology • Psoriasis

Incidental Discovery of Celiac Disease in a Patient with Mycosis Fungoides (ACG 2025) - "Her past medical history includes hypertension and ANA-positive inflammatory arthritis managed with losartan, hydroxychloroquine and low-dose prednisone, as well as surgical resection of an ovarian adenofibroma. Her mycosis fungoides had been treated with multiple modalities including UVB therapy (discontinued due to lack of response), bexarotene (discontinued due to hypertriglyceridemia), mogamulizumab (discontinued due to lack of response) and Acitretin with topical tretinoin cream...Inadequate response to oral vitamin A supplementation suggests ongoing malabsorption. This case highlights the importance of considering CD in patients with unexplained vitamin deficiencies, even in the absence of gastrointestinal complaints.Figure: Skin lesion characteristic of Mycosis fungoides"

Clinical • Cardiovascular • Celiac Disease • Cutaneous T-cell Lymphoma • Dermatology • Dyslipidemia • Hypertension • Hypertriglyceridemia • Immunology • Inflammatory Arthritis • Mycosis Fungoides • Oncology • Rheumatology • Solid Tumor • CFTR • ELANE

Super Responders in Plaque Psoriasis: A Real-World, Multi-Agent Analysis Showing Bimekizumab Associated with the Highest Odds of PASI = 0 at Week 12. (PubMed, J Clin Med) - " We performed a retrospective, single-center study of 116 adults with moderate-to-severe plaque psoriasis initiating their first biologic (adalimumab, tildrakizumab, guselkumab, risankizumab, bimekizumab, or secukinumab)...Multivariable logistic regression estimated adjusted associations between biologic and SR, controlling for age, sex, disease duration, BMI, baseline PASI, and prior cyclosporine/acitretin... In this real-world cohort, biologic selection-particularly bimekizumab-was the main determinant of early complete clearance. These findings highlight mechanistic class as a key driver of rapid, deep responses and support prospective validation with harmonized SR definitions and extended follow-up."

Journal • Real-world evidence • Dermatology • Immunology • Psoriasis

Serious Infection Risk with Systemic Treatments for Psoriasis: A Systematic Review and Network Meta-analysis Combining Randomised and Non-randomised Evidence. (PubMed, Dermatol Ther (Heidelb)) - "The tumour necrosis factor alpha (TNFα) inhibitors adalimumab and infliximab had higher risk of serious infections in the combined NMA. Our findings may inform clinicians and patients concerned about the risk of emergent serious infection on therapy."

Journal • Retrospective data • Review • Dermatology • Immunology • Infectious Disease • Oncology • Psoriasis

Lamellar Ichthyosis Improvement With Acitretin and Dupilumab. (PubMed, JAMA Dermatol) - No abstract available

Journal • Atopic Dermatitis • Dermatology • Immunology • Vitiligo

A Rare Familial Case of Harlequin Ichthyosis in an Infant of a Diabetic Mother: A Diagnostic and Management Challenge in Low and Middle Income Settings. (PubMed, Clin Case Rep) - "Oral acitretin was started at 1.1 mg/kg/day along with intensive supportive care but the neonate had become septic and succumbed on day nine despite multi-antibiotic therapy, intravenous fluid resuscitation, and oral retinoid therapy...The case highlights the intersection of maternal comorbidities, consanguinity, and healthcare system gaps in aggravating HI outcomes in LMICs. It necessitates emergent interventions such as subsidized prenatal screening, genetic counseling outreach, particularly concerning maternal diabetes, additional research, consanguineous marriage counseling, and neonatal infection control to enhance prognosis and prevent recurrence."

Journal • Atopic Dermatitis • Critical care • Dermatology • Diabetes • Gestational Diabetes • Immunology • Infectious Disease • Metabolic Disorders • Septic Shock • Vitiligo

Cohort study on the survival of methotrexate and acitretin treatment in patients with plaque psoriasis: experience from a single center. (PubMed, An Bras Dermatol) - No abstract available

Journal • Dermatology • Immunology • Psoriasis

A case report of plaque psoriasis comorbid with hidradenitis suppurativa, hepatitis B, and colorectal cancer treated with xeligekimab. (PubMed, Front Immunol) - "Previous treatment with topical corticosteroids, Calcipotriol Betamethasone Ointment and acitretin provided poor control of psoriasis, resulting in significant quality-of-life impairment. Xeligekimab demonstrated significant efficacy and acceptable safety over 28 weeks in this complex case of psoriasis with concurrent hidradenitis suppurativa, chronic hepatitis B, and metastatic colorectal cancer. Extended follow-up is ongoing to evaluate long-term outcomes, while larger prospective studies are warranted to validate biologic therapy for such multimorbid presentations."

Journal • Colorectal Cancer • Dermatology • Hepatitis B • Hidradenitis Suppurativa • Immunology • Infectious Disease • Oncology • Psoriasis • Solid Tumor • IL17A

Early diagnosis of a case of lipoid proteinosis due to an undescribed deletion in ECM1 gene. (PubMed, J Dtsch Dermatol Ges) - No abstract available

Journal • Dermatology • Otorhinolaryngology

Evaluating the Role of Disease Duration in Systemic Therapy Response Among Patients with Moderate-to-Severe Psoriasis. (PubMed, Psoriasis (Auckl)) - "Adult patients with moderate to severe psoriasis receiving systemic therapy (including biologics, methotrexate or acitretin) were divided into groups based on disease duration: <2 years, 2~10 years, and ≥10 years. Disease duration does not significantly affect clinical efficacy or patients reported outcomes in patients with moderate-to-severe psoriasis receiving systemic therapy. These results indicate that early systemic therapy does not improve treatment outcomes in real clinical settings, thereby supporting the continued efficacy of step-up treatment strategy and providing novel insights into clinical practice management."

Journal • CNS Disorders • Depression • Dermatology • Immunology • Inflammation • Mood Disorders • Psoriasis • Psychiatry

HIV-Associated Pityriasis Rubra Pilaris Type 6: First Case Report from Türkiye. (PubMed, Infect Dis Clin Microbiol) - "The CD4+ T lymphocyte count was 522/µL, and the viral load was 19,100 copies/µL. Treatment with acitretin and antiretroviral therapy was initiated, and the patient responded well within three months."

Journal • Human Immunodeficiency Virus • Infectious Disease • CD4

Drug survival of systemic treatments for severe paediatric psoriasis: An international retrospective study. (PubMed, J Eur Acad Dermatol Venereol) - "This cohort study showed that acitretin and methotrexate had comparable 2-year drug survival rates, which were superior to cyclosporine. We did not find any predictive factors for increased treatment maintenance except for first-line use of acitretin. AEs were a frequent reason for discontinuing treatments. These results may help develop treatment algorithms for systemic therapy in paediatric psoriasis."

Journal • Retrospective data • Dermatology • Immunology • Inflammation • Inflammatory Arthritis • Pediatrics • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Spesolimab as treatment option for refractory Acrodermatitis Continua of Hallopeau (EADV 2025) - "Following this, she was treated with various systemic therapies (acitretin, fumaric acid esters, glucocorticoids, methotrexate, cyclosporine), several biologics (ustekinumab, secukinumab, adalimumab, ixekizumab, guselkumab, apremilast, anakinra, infliximab, risankizumab, brodalumab, bimekizumab, tildrakizumab), Janus kinase inhibitors (tofacitinib, upadacitinib), and a combination of both (risankizumab and tofacitinib)...After the second dose, the patient noted signs of effluvium, which were subsequently treated with topical minoxidil... This case highlights the successful application of spesolimab, a targeted IL-36 inhibitor, as a novel treatment option for a patient suffering from severe refractory acrodermatitis continua of Hallopeau (ACH). To the best of our knowledge, this is the first case of treating acrodermatitis continua of Hallopeau (ACH) with subcutaneous spesolimab.The emergence of effluvium as a potential side effect following treatment necessitates careful..."

Cardiovascular • Dermatitis • Dermatology • Diabetes • Immunology • Metabolic Disorders • Musculoskeletal Pain • Osteoarthritis • Psoriasis • Pulmonary Arterial Hypertension • Pustular Psoriasis • Rheumatology • Type 2 Diabetes Mellitus

Immune checkpoint inhibitor–induced psoriasis successfully treated with tildrakizumab in an oncologic patient (EADV 2025) - " We present the case of a 53-year-old male with stage IVB squamous cell carcinoma of the lung (PD-L1 50%) enrolled in a clinical trial receiving combination immunotherapy with dostarlimab (anti–PD-1), belrestotug (anti– TIGIT), and nelistotug (anti–CD96)...Initial treatment with topical corticosteroids and vitamin D analogues plus oral acitretin at 25 mg/day for three months failed to produce significant improvement, the Psoriasis Area and Severity Index (PASI) was 12, body surface area (BSA) 10%, and Physician Global Assessment (PGA) 3... IL-23 inhibitors, such as tildrakizumab, have demonstrated a favorable safety profile in both clinical trials and real- world settings, including in patients with malignancies. In this case, tildrakizumab provided a fast and sustained therapeutic response in immune checkpoint inhibitor–induced psoriasis refractory to standard treatments, with no compromise in oncologic control. This case highlights its potential role in managing severe..."

Checkpoint inhibition • Clinical • Dermatology • Immunology • Inflammatory Arthritis • Lung Cancer • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Solid Tumor • Squamous Cell Carcinoma • CD96 • IL23A • PD-L1 • TIGIT

Efficacy and safety of cyclosporine a combined with acitretin in moderate-to-severe plaque psoriasis: a randomized controlled trial. (PubMed, Front Med (Lausanne)) - P4 | "This regimen may represent a cost-effective therapeutic option for patients not eligible for biologic therapy. https://www.chictr.org.cn, ID register: ChiCTR-OPN-17013383."

Journal • Cardiovascular • Dermatology • Dyslipidemia • Hypertension • Immunology • Metabolic Disorders • Psoriasis

Systematized Linear Porokeratosis, with Underlying Mevalonate Kinase Mutation, Treated with a Combination of Radiosurgery and Oral Acitretin. (PubMed, Indian Dermatol Online J) - No abstract available

Journal

The evolving genetic landscape of ILVEN: A comprehensive review. (PubMed, J Eur Acad Dermatol Venereol) - "Somatic mutations in CARD14 activate NF-κB and IL-12/23/IL-17 signalling pathways and may be responsive to biologics such as secukinumab and ustekinumab...KRT10 mutations, which affect keratinocyte differentiation, show favourable responses to crisaborole and acitretin...The molecular characterization of ILVEN and related disorders supports a shift toward precision dermatology. As accessibility increases, genotype-directed therapy may replace empiric approaches with more targeted, effective and personalized management frameworks."

Journal • Review • Dermatology • Inflammation • Rare Diseases • ABCA1 • GJA1 • HRAS • IL12A • KRT10

Atypical manifestation of psoriasis in the elderly: possible expression of Mal de Meleda diagnosis review and case report. (PubMed, Front Med (Lausanne)) - "Systemic retinoids, particularly acitretin, have demonstrated efficacy in reducing epidermal hyperkeratosis and enhancing clinical outcomes...Distinctive diagnostic clues-such as very early disease onset, autosomal recessive mode of inheritance, and the hallmark transgradient pattern of palmoplantar keratoderma-can aid in distinguishing MDM from the more prevalent psoriasis vulgaris. Although biologic therapies targeting TNF-α and IL-17A have shown limited efficacy in MDM, systemic retinoids continue to represent a clinically effective therapeutic option for managing this rare genodermatosis."

Journal • Crohn's disease • Dermatology • Gastroenterology • Genetic Disorders • Idiopathic Arthritis • Immunology • Inflammatory Bowel Disease • Obesity • Oncology • Pediatrics • Psoriasis • Rheumatology • IL17A • MAL

Impact of temperature trend-defined seasonality on psoriasis treatment outcomes: a multicenter longitudinal study. (PubMed, Front Immunol) - "Data were derived from the Shanghai Psoriasis Effectiveness Evaluation CoHort (SPEECH), a prospective, multicenter registry assessing the effectiveness of biologics (adalimumab, ustekinumab, secukinumab and ixekizumab), conventional systemic therapies (acitretin and methotrexate), and phototherapy. Cooling trends are associated with reduced treatment efficacy independently of static temperature, humidity, and ultraviolet levels. This BMI-modified effect underscores the importance of personalized management strategies addressing both environmental and patient-specific factors."

Journal • Observational data • Dermatology • Immunology • Psoriasis

Semaglutide in the treatment of a patient with type 2 diabetes mellitus, psoriasis, and metabolic dysfunction-associated steatotic liver disease: a case report. (PubMed, Front Med (Lausanne)) - "Initial therapies, including acitretin and topical agents, failed to yield clinical improvement. Semaglutide was initiated at 0.25 mg/week, titrated to 1 mg/week over 12 weeks, alongside metformin dose adjustment. At 24 weeks, the patient exhibited significant improvements: HbA1c decreased from 9.8 to 7.2%, body weight reduced by 6 kg, liver enzymes returned to normal ranges, and PASI declined to 6.2. Treatment was well-tolerated with no severe adverse events."

Journal • Dermatology • Diabetes • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Psoriasis • Type 2 Diabetes Mellitus

Improvement in Hailey Hailey patient undergoing Baricitinib therapy (EADV 2025) - "The previous treatment with Neotigason for 1 year showed no improvement...Also an unsuccessful treatment with doxycycline and Botox injections followed. Further treatments with Dapsone, Otezla and Bimekizumab were discontinued due to lack of effect or side effects... Hailey-Hailey disease is a rare genodermatosis with an autosomal dominant inheritance pattern, characterized by compromised adhesion between epidermal keratinocytes. It has an estimated prevalence of 1/50,000 and it results from a heterozygous mutation in the ATP2C1 gene, which causes changes in the synthesis of junctional proteins, leading to acantholysis. It usually begins in adulthood."

Clinical • Alopecia • Atopic Dermatitis • CNS Disorders • Dermatitis • Dermatology • Genetic Disorders • Immunology • Inflammatory Arthritis • Multiple Sclerosis • Pruritus • Rheumatoid Arthritis • Rheumatology

Investigation of Hepatitis B Reactivation Risk in Psoriasis Patients with Prior HBV Exposure Under Immunosuppressive Therapy (EADV 2025) - "Treatment options include conventional agents such as Methotrexate (MTX), Cyclosporine, and Acitretin, as well as biologics targeting cytokines like TNF-alpha, IL-12/23, IL-17, and IL-23...The current treatments used by the patients included: Ixekizumab (22.4%), Secukinumab (19.4%), MTX (15.3%), Risankizumab (13.3%), Ustekinumab (10.2%), Guselkumab (10.2%), Adalimumab (7.1%), Cyclosporine (1.0%), and Certolizumab (1.0%)...Reactivation rates by drug were: MTX 13.3% (n=2), Guselkumab 10.0% (n=1), Ixekizumab 4.5% (n=1), Secukinumab 5.3% (n=1); no reactivation was observed in patients on other treatments... Previous studies investigating HBV reactivation under immunosuppressive therapy have reported rates ranging from 0% to 14.8%. In our study, this rate was 5.1%, which may vary depending on the patient's HBV serological status, the immunosuppressive agent used, and the duration of therapy. HBV screening, monitoring, and prophylaxis, when necessary, are essential during..."

Clinical • Dermatology • Hepatitis B • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Failure • Psoriasis • IL12A • IL17A • IL23A • TNFA

Real-world experience with tildrakizumab in moderate-to-severe psoriasis (EADV 2025) - "Prior treatments included systemic therapies such as methotrexate (45.8%), acitretin (25%), cyclosporine (16.7%), apremilast (12.5%), and biologics such as TNF inhibitors (54.2%), ustekinumab (35.4%), secukinumab (12.5%), and ixekizumab (12.5%). Tildrakizumab proved to be an effective and well-tolerated treatment for moderate-to-severe psoriasis, significantly reducing PASI scores in most patients. Discontinuation occurred in a minority of cases, mainly due to lack of efficacy or unrelated health issues. These real-world results support tildrakizumab as a promising therapeutic option, particularly for patients who have not responded to prior systemic therapies."

Clinical • Real-world • Real-world evidence • Dermatology • Diabetes • Dyslipidemia • Genetic Disorders • Hypertension • Immunology • Lung Cancer • Metabolic Disorders • Obesity • Psoriasis • Solid Tumor • IL23A

Physician-Reported Treatment Patterns in Moderate to Severe Chronic Hand Eczema: the RWEAL Multinational Medical Chart Review. (PubMed, Dermatol Ther (Heidelb)) - "Despite being a first-line treatment, 40% of patients with CHE were inadequately treated with or contraindicated to TCS. Over one-quarter of patients progressed to phototherapy or systemic therapy. These results suggest a lack of effective and well-tolerated topical treatment options in CHE. Graphical Abstract available for this article."

Journal • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology